-
公开(公告)号：US20230390227A1
公开(公告)日：2023-12-07
申请号：US18453937
申请日：2023-08-22
发明人： Fredric Jay COHEN
CPC分类号： A61K31/18 , A61P3/12 , G01N33/5014 , A61K45/06
摘要： Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate to treat an associated disease or disorder. The method comprises administering to the subject a therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof, and monitoring the subject for signs and symptoms of toxicity and clinical response associated with the OAT1 substrate.
-
公开(公告)号：US20230201252A1
公开(公告)日：2023-06-29
申请号：US18117315
申请日：2023-03-03
IPC分类号： A61K33/00 , A23L33/19 , A23L33/00 , A23L33/175 , A23L33/16 , A23L33/125 , A23L33/15 , A61P3/12 , A61B5/11 , A61B5/00 , A61K9/00 , A61K31/198 , A61K31/405 , A61K31/7004 , A61K38/00 , A61K47/10 , A61K47/36 , A61K47/42
CPC分类号： A61K33/00 , A23L33/19 , A23L33/30 , A23L33/175 , A23L33/16 , A23L33/125 , A23L33/15 , A23L33/40 , A61P3/12 , A61B5/1118 , A61B5/4875 , A61B5/6887 , A61B5/7275 , A61K9/0053 , A61K31/198 , A61K31/405 , A61K31/7004 , A61K38/00 , A61K47/10 , A61K47/36 , A61K47/42 , A23V2002/00 , A61B5/0082 , A61B5/026
摘要： A hydration system including a plurality of hydration compositions for improving vascular health is provided. A hydration system comprises a first hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight, sodium, potassium, and one or more essential amino acids, a second hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight, sodium, potassium, and a hydrogel, a pectin based additive, a starch, or a glycerin and a third hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight and at least one of electrolytes or glucose, vitamins and minerals. The hydration compositions may be formulated for oral or enteral administration.
-
公开(公告)号：US20190209607A1
公开(公告)日：2019-07-11
申请号：US16099029
申请日：2017-05-05
申请人： Tricida, Inc.
发明人： Gerrit KLAERNER , Eric F. CONNOR , Randi K. GBUR , Matthew J. KADE , Paul H. KIERSTEAD , Jerry M. BUYSSE , Michael J. COPE , Kalpesh N. BIYANI , Son H. NGUYEN , Scott M. TABAKMAN
IPC分类号： A61K31/785 , A61P3/12
CPC分类号： A61K31/785 , A61K9/0053 , A61P3/12 , A61P13/12 , A61P43/00 , C08F8/02 , C08F226/02 , C08F226/04
摘要： Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
-
公开(公告)号：US12090168B2
公开(公告)日：2024-09-17
申请号：US16761107
申请日：2018-11-03
发明人： Molly Krisann Gibson , Nathan Wilson Stebbins , Ruth Thieroff-Ekerdt , Geoffrey A. von Maltzahn
IPC分类号： A61K31/716 , A61K35/741 , A61K47/10 , A61P3/12
CPC分类号： A61K31/716 , A61K35/741 , A61K47/10 , A61P3/12
摘要： Compositions, e.g., pharmaceutical compositions, nutritional compositions, medical foods, and food ingredients, as well as their methods of use, are provided, for treating diseases associated with hyperammonemia, e.g., urea cycle disorders (UCD) and hepatic encephalopathy (HE), e.g., minimal HE (MHE) and overt HE (OHE), and modulating enzyme activities and levels of microbes and taxa, and metabolites (e.g., ammonia) in the microbiome of a subject.
-
公开(公告)号：US20240226225A1
公开(公告)日：2024-07-11
申请号：US18285203
申请日：2022-03-31
IPC分类号： A61K38/00 , A61P3/12 , C07K1/107 , C07K14/575
CPC分类号： A61K38/00 , A61P3/12 , C07K1/1077 , C07K14/575
摘要： The present invention generally relates to peptide analogues, including both monomers and dimers, exhibiting hepcidin activity with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof in the treatment and/or prevention of conditions or disorders, including erythrocytoses, such as polycytemia vera, iron overload diseases such as hereditary hemochromatosis: iron-loading anemias, and other conditions and disorders.
-
公开(公告)号：US20230201253A1
公开(公告)日：2023-06-29
申请号：US18117321
申请日：2023-03-03
IPC分类号： A61K33/00 , A23L33/19 , A23L33/00 , A23L33/175 , A23L33/16 , A23L33/125 , A23L33/15 , A61P3/12 , A61B5/11 , A61B5/00 , A61K9/00 , A61K31/198 , A61K31/405 , A61K31/7004 , A61K38/00 , A61K47/10 , A61K47/36 , A61K47/42
CPC分类号： A61K33/00 , A23L33/15 , A23L33/16 , A23L33/19 , A23L33/30 , A23L33/40 , A23L33/125 , A23L33/175 , A61B5/1118 , A61B5/4875 , A61B5/6887 , A61B5/7275 , A61K9/0053 , A61K31/198 , A61K31/405 , A61K31/7004 , A61K38/00 , A61K47/10 , A61K47/36 , A61K47/42 , A61P3/12 , A23V2002/00 , A61B5/026 , A61B5/0082
摘要： Systems and methods for administering one or more hydration compositions to an individual to improve vascular health are provided. A system comprises a hydration composition delivery element and a sensor operatively coupled to the hydration composition delivery element. The sensor is configured to determine one or more of the intake of fluids, the amount of fluid discharged, the activity level of the patient, or level of hydration of the patient based on the level of fluid in the hydration composition delivery element. The system further includes a monitoring system which, based on a signal received from the sensor, provides an indication of one or more of the need to intake fluid, the identity of a specific hydration composition of a plurality of hydration compositions to be consumed or an amount of a hydration composition to be consumed.
-
公开(公告)号：US20180319783A1
公开(公告)日：2018-11-08
申请号：US15769148
申请日：2016-10-21
发明人： Franz Dürrenberger , Michael Burgert , Susanna Burckhardt , Wilm Buhr , Aris Kalogerakis , Stefan Reim , Vania Manolova , Susan Boyce , Christopher John Yarnold , Paula Pena , Jon Shepherd , Cristina Lecci , Richard Jarjes-Pike , John Scott
IPC分类号： C07D413/14 , C07D417/14 , C07D417/12 , C07D413/04 , C07D401/14 , C07D403/14 , C07D471/04 , C07D487/04 , A61P25/16 , A61P25/28 , A61P3/12 , A61P7/06
CPC分类号： C07D413/14 , A61K31/16 , A61K31/4184 , A61K31/426 , A61K31/427 , A61K31/435 , A61K31/4355 , A61K31/437 , A61K31/4375 , A61K31/4422 , A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K36/9066 , A61K45/06 , A61K2300/00 , A61P3/12 , A61P7/06 , A61P25/16 , A61P25/28 , C07D277/56 , C07D401/14 , C07D403/14 , C07D413/04 , C07D417/12 , C07D417/14 , C07D471/04 , C07D487/04 , Y02A50/411
摘要： The invention relates to novel compounds of the general formula (A-I), with Het-2 being an optionally substituted bicyclic heteroaryl of the formula (AA) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
-
公开(公告)号：US20240317719A1
公开(公告)日：2024-09-26
申请号：US18397454
申请日：2023-12-27
申请人： Ardelyx, Inc.
发明人： Dean DRAGOLI , Irina DOTSENKO , Jason LEWIS
IPC分类号： C07D403/14 , A61K47/55 , A61P1/00 , A61P1/10 , A61P3/12 , A61P9/04 , A61P9/12 , A61P29/00 , C07D241/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D487/08
CPC分类号： C07D403/14 , A61K47/55 , A61P1/00 , A61P1/10 , A61P3/12 , A61P9/04 , A61P9/12 , A61P29/00 , C07D241/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D487/08
摘要： The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.
-
公开(公告)号：US20240293511A1
公开(公告)日：2024-09-05
申请号：US18570004
申请日：2022-06-14
摘要： The disclosure provides methods for the treatment and/or prevention of iron overload diseases such as hereditary hemochromatosis.
-
公开(公告)号：US20240277607A1
公开(公告)日：2024-08-22
申请号：US18643713
申请日：2024-04-23
IPC分类号： A61K9/00 , A61K31/198 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K31/7004 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/14 , A61K33/24 , A61K33/30 , A61K33/32 , A61K33/34 , A61K33/42 , A61K36/48 , A61P3/02 , A61P3/12 , A61P3/14
CPC分类号： A61K9/0029 , A61K31/198 , A61K31/401 , A61K31/405 , A61K31/4172 , A61K31/7004 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/14 , A61K33/24 , A61K33/30 , A61K33/32 , A61K33/34 , A61K33/42 , A61K36/48 , A61P3/02 , A61P3/12 , A61P3/14
摘要： A parenteral nutrition including at least one of an amino acid, a dextrose, a lipid, an electrolyte or a mixture thereof and a trace element including at least one of zinc, copper, selenium, or manganese is provided. The parenteral nutrition including the trace element is stable for about at least 3 days to about 14 days. Methods of preparing and using the stable injectable parenteral nutrition are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.035 秒)
